Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
复制标题
DOI：
10.1002/hep.27488
复制
发表时间：
2015-08-01
期刊：
影响因子：
13.5
通讯作者：
Hernandez, Adrian F.
中科院分区：
文献类型：
--
作者：
Ahmad, Tariq;Yin, Philip;Hernandez, Adrian F.
慢性丙型肝炎病毒（HCV）感染的治疗正在从基于干扰素（IFN）的治疗发展为直接作用抗病毒（DAA）药物，但出现了一些涉及心脏毒性的安全问题。在这项研究中，我们试图更好地了解新型 DAA 的潜在脱靶毒性。我们回顾性评估了一项 II 期研究中哨点病例的临床和病理结果，该研究导致 BMS-986094（一种 HCV 核苷酸聚合酶（非结构 5B）抑制剂）的临床开发终止。我们还报告了同一研究中其他患者的结果，包括心电图变化、心血管生物标志物和经胸超声心动图。 34 名患者接受了不含 IFN 的 BMS-986094 治疗方案。六名患者有左心室射血分数 (LVEF)
Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity. In this study, we sought to better understand the potential off-target toxicities of new DAAs. We retrospectively evaluated the clinical and pathological findings of the sentinel case in a phase II study that led to clinical development discontinuation for BMS-986094, an HCV nucleotide polymerase (nonstructural 5B) inhibitor. We also report on outcomes from other patients in the same study, including electrocardiogram changes, cardiovascular biomarkers, and transthoracic echocardiograms. Thirty-four patients received IFN-free BMS-986094 regimens. Six patients had left ventricular ejection fractions (LVEFs)